Share on LinkedInShare on LinkedIn

ARTICLE · 21 APRIL 2026

HSR Rules In Transition - Practical Guidance For Healthcare And Life Sciences Transactions

Baker Botts L.L.P.
Baker Botts L.L.P.
Contributor
Baker Botts L.L.P.

Baker Botts L.L.P.

Baker Botts is a leading international law firm with 11 offices located in the US, Europe, and the...

View firm profile
Explore more from Baker Botts L.L.P.

Our Antitrust Health Horizons webinar series focuses on how life sciences and healthcare companies should navigate a rapidly evolving HSR landscape—and what to do now as premerger notification requirements continue to shift.

United StatesAntitrust/Competition Law

Our Antitrust Health Horizons webinar series focuses on how life sciences and healthcare companies should navigate a rapidly evolving HSR landscape—and what to do now as premerger notification requirements continue to shift.

HSR premerger notification requirements remain in flux. While the prior HSR reporting form is currently back in effect, the 2025 Updated Form, its subsequent vacatur and appeal, and the agencies’ recent request for public comments on the effectiveness of the Updated Form all point in the same direction: more upfront disclosure, more need for strategic antitrust advice, and more scrutiny during the HSR period. Whether the 2025 Updated Form returns or a revised version replaces it, companies should expect continued pressure on deal timing, preparation, and internal coordination.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from